Volume 117, Issue 3, Pages (September 1999)

Slides:

Advertisements

Similar presentations

Celiac Disease Genetics: Current Concepts and Practical Applications Ludvig M. Sollid, Benedicte A. Lie Clinical Gastroenterology and Hepatology Volume.

Advertisements

Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease Richard N. Fedorak, *, Alfred Gangl, ‡, Charles.

Antibodies to CBir1 Flagellin Define a Unique Response That Is Associated Independently With Complicated Crohn’s Disease Stephan R. Targan, Carol J. Landers,

Crohn's disease Prof Daniel C Baumgart, MD, Prof William J Sandborn, MD The Lancet Volume 380, Issue 9853, Pages (November 2012) DOI: /S (12)

Volume 117, Issue 2, Pages (August 1999)

Volume 115, Issue 3, Pages (September 1998)

Guillaume Bouguen, Barrett G. Levesque, Brian G

Volume 146, Issue 3, Pages e1 (March 2014)

Certolizumab Pegol in Patients With Moderate to Severe Crohn's Disease and Secondary Failure to Infliximab William J. Sandborn, Maria T. Abreu, Geert.

Abatacept for Crohn's Disease and Ulcerative Colitis

Volume 135, Issue 4, Pages (October 2008)

Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set Christopher.

Volume 133, Issue 1, Pages (July 2007)

An oral supplement enriched with fish oil, soluble fiber, and antioxidants for corticosteroid sparing in ulcerative colitis: A randomized, controlled.

Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease Stephen B Hanauer, Carrie L Wagner,

Volume 154, Issue 1, Pages e6 (January 2018)

Effect of the Prebiotic Oligofructose on Relapse of Clostridium difficile-Associated Diarrhea: A Randomized, Controlled Study Stephen Lewis, Stephen.

Volume 120, Issue 6, Pages (May 2001)

Risks and Benefits of Infliximab for the Treatment of Crohn’s Disease

Volume 153, Issue 1, Pages e6 (July 2017)

Oral pentasa in the treatment of active Crohn’s disease: A meta-analysis of double- blind, placebo-controlled trials Stephen B Hanauer, Ulf Strömberg

Association Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease Jean–Frédéric Colombel, William.

Volume 115, Issue 1, Pages (July 1998)

GI clinical research 2002–2003: the year in review

Gary R. Lichtenstein, Brian G. Feagan, Russell D. Cohen, Bruce A

Antje Timmer*, Lloyd R. Sutherland*,‡, Francois Martin§

Association of Trough Serum Infliximab to Clinical Outcome After Scheduled Maintenance Treatment for Crohn’s Disease Elana A. Maser, Renata Villela,

Lisa L. Amsterdam, M. D. , William Gentry, M. D. , Smeta Jobanputra, M

Infliximab Prevents Crohn's Disease Recurrence After Ileal Resection

Volume 130, Issue 2, Pages (February 2006)

Volume 147, Issue 3, Pages e3 (September 2014)

Volume 123, Issue 2, Pages (August 2002)

Volume 146, Issue 1, Pages e1 (January 2014)

Issue Highlights Clinical Gastroenterology and Hepatology

Safety of Celecoxib in Patients With Ulcerative Colitis in Remission: A Randomized, Placebo-Controlled, Pilot Study William J. Sandborn, William F. Stenson,

Severe Constipation Clinical Gastroenterology and Hepatology

A Test-based Strategy Is More Cost Effective Than Empiric Dose Escalation for Patients With Crohn's Disease Who Lose Responsiveness to Infliximab Fernando.

Volume 132, Issue 5, Pages (May 2007)

Volume 117, Issue 2, Pages (August 1999)

Volume 119, Issue 6, Pages (December 2000)

William J. Sandborn, Stefan Schreiber, Brian G

Volume 119, Issue 6, Pages (December 2000)

Volume 154, Issue 6, Pages (May 2018)

Volume 132, Issue 1, Pages (January 2007)

Brian G. Feagan, Gordon R. Greenberg, Gary Wild, Richard N

David H. Bruining, William J. Sandborn

Volume 114, Issue 6, Pages (June 1998)

Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease Gerassimos J.

Volume 115, Issue 3, Pages (September 1998)

Volume 121, Issue 5, Pages (November 2001)

Initiating Azathioprine for Crohn's Disease

Correlation Between the Crohn's Disease Activity and Harvey–Bradshaw Indices in Assessing Crohn's Disease Severity Severine Vermeire, Stefan Schreiber,

Volume 126, Issue 2, Pages (February 2004)

Volume 128, Issue 7, Pages (June 2005)

Volume 132, Issue 1, Pages (January 2007)

Volume 135, Issue 2, Pages (August 2008)

Reinduction With Certolizumab Pegol in Patients With Relapsed Crohn's Disease: Results From the PRECiSE 4 Study William J. Sandborn, Stefan Schreiber,

Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma William.

Volume 142, Issue 5, Pages e2 (May 2012)

AGA technical review on osteoporosis in gastrointestinal diseases

Volume 117, Issue 4, Pages (October 1999)

Volume 128, Issue 7, Pages (June 2005)

Volume 132, Issue 3, Pages (March 2007)

Volume 128, Issue 4, Pages (April 2005)

Medical Therapy for Refractory Pediatric Crohn’s Disease

Volume 121, Issue 2, Pages (August 2001)

Assessing activity of pediatric Crohn's disease: Which index to use?

Continuous Therapy With Certolizumab Pegol Maintains Remission of Patients With Crohn's Disease for up to 18 Months Gary R. Lichtenstein, Ole Ø. Thomsen,

Study design. Study design. Patients who completed the 8-week induction study and achieved clinical response-100 (decrease in Crohn's disease activity.

(A) Percentage of patients achieving remission or response at week 12 or 24 after initiating ova therapy. (A) Percentage of patients achieving remission.

Presentation transcript:

Volume 117, Issue 3, Pages 527-535 (September 1999) Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease William J. Sandborn, William J. Tremaine, Douglas C. Wolf, Stephan R. Targan, Charles A. Sninsky, Lloyd R. Sutherland, Stephen B. Hanauer, John W.D. McDonald, Brian G. Feagan, Richard N. Fedorak, Kim L. Isaacs, M.Gennette Pike, Dennis C. Mays, James J. Lipsky, Susan Gordon, Christi S. Kleoudis, Robert H. Murdock Gastroenterology Volume 117, Issue 3, Pages 527-535 (September 1999) DOI: 10.1016/S0016-5085(99)70445-2 Copyright © 1999 American Gastroenterological Association Terms and Conditions

Fig. 1 Percentages of patients with Crohn's disease with improvement or remission at each study visit, according to treatment group. ▨, Placebo; ▧, IV AZA. There were no significant differences between the 2 groups at any time point. (A) Complete remission (CDAI score < 150 points and total steroid withdrawal). (B) Clinical remission (CDAI score < 150 points). (C) Improvement (CDAI score < 150 points or total steroid withdrawal). (D) Improvement (decrease in CDAI score from baseline ≥ 70 points). Gastroenterology 1999 117, 527-535DOI: (10.1016/S0016-5085(99)70445-2) Copyright © 1999 American Gastroenterological Association Terms and Conditions

Fig. 2 Median scores or values at each study visit according to treatment group. ●, Placebo; ▴, IV AZA. The only significant differences between the 2 groups at any of the time points are those indicated in the figure. (A) CDAI and IBDQ quality of life index. (B) Prednisone dose. (C) RBC 6TGN nucleotide concentrations. (D) Total WBC concentrations. Gastroenterology 1999 117, 527-535DOI: (10.1016/S0016-5085(99)70445-2) Copyright © 1999 American Gastroenterological Association Terms and Conditions